Emerging research suggest this peptide, a dual stimulator targeting both GLP-1 and GIP , may provide a promising advancement for obesity loss . Early clinical trials have shown substantial decreases in body tissue, potentially outperforming current body composition medications . However , further assessment is needed to thoroughly assess its long-t